PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
PURE BIOSCIENCE, INC.
Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 15, 2026
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026
- Market cap
- $7.33M
- P/E (TTM)
- –
- Dividend yield
- –
Pure Bioscience statistics
Financials through Apr 30, 2026, price as of Oct 19, 2026, median of Miscellaneous Chemical Products companies for comparison
Valuation
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Market Cap | $8.59M | $197.05M |
| Enterprise Value | $7.61M | $106.56M |
| PS Ratio | 3.55 | 3.93 |
Enterprise value
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| EV / Sales | 3.15 | 2.69 |
Income (trailing twelve months)
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Revenue | $2.42M | $57.94M |
| Gross Profit | $1.43M | $90.47M |
| Operating Income | -$1.92M | -$21.44M |
| Net Income | -$2.21M | -$22.46M |
| EBITDA | -$1.92M | -$16.91M |
| EPS (Diluted) | -$0.02 | -$0.83 |
Margins
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Gross Margin | 58.9% | 52.3% |
| Operating Margin | -79.2% | -44.5% |
| Profit Margin | -91.2% | -39.2% |
| EBITDA Margin | -79.2% | -31.3% |
Returns
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Return on Assets (ROA) | -168.6% | -41.0% |
Growth
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 26.8% | 6.01% |
| Revenue Growth (3Y CAGR) | 6.63% | 2.25% |
| Revenue Growth (5Y CAGR) | -20.5% | 6.42% |
Balance sheet
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $983.00K | $62.42M |
| Net Cash (Debt) | $983.00K | $15.68M |
| Net Cash Per Share | $0.01 | $0.65 |
| Equity (Book Value) | -$5.84M | $48.79M |
| Book Value Per Share | -$0.04 | $1.36 |
| Tangible Book Value | -$5.84M | $23.06M |
| Working Capital | -$2.11M | $75.77M |
Financial position
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Current Ratio | 0.42 | 3.30 |
| Quick Ratio | 0.34 | 2.39 |
| Interest Coverage | -4.91 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.78M | -$12.35M |
Efficiency
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Asset Turnover | 1.85 | 0.38 |
| Inventory Turnover | 5.49 | 2.67 |
| Revenue Per Employee | $219.91K | $398.96K |
| Profits Per Employee | -$200.46K | -$732.08K |
| Employee Count | 11 | 73 |
Dividends and yields
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -25.7% | -21.2% |
Shares
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 130,018,000 | 59,128,900 |
| Shares Change (YoY) | -0.21% | 11.1% |
| Shares Change (QoQ) | 16.2% | 0.54% |
| Float | 130,005,000 | 48,744,500 |
| Shares Held by Insiders | 0.01% | 11.8% |
Scores
| Measure | Pure Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | -130.01 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Pure Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.